Pricing Log in Create free account

BridgeBio Pharma, Inc. (BBIO) vs Exelixis, Inc. (EXEL)

BridgeBio Pharma, Inc. and Exelixis, Inc. are both Biotechnology companies. Exelixis, Inc. is the larger, with a market value of $16.8B against $14.5B — 1.2× the size. BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Exelixis, Inc. trades at 19.9×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 167.3% against 9.12%. Exelixis, Inc. has the higher net margin (35.5% vs −62.6%) and the higher return on invested capital (66.6% vs 0.00%). Across the 18 metrics below, Exelixis, Inc. leads on 14 and BridgeBio Pharma, Inc. on 4.

Valuation

Metric BBIO EXEL Biotechnology median
P/E n/m 19.89 10.26
P/S 15.49 6.80 9.18
P/B n/m 9.26 2.05
Price to free cash flow n/m 14.84 24.81
EV/EBITDA n/m 15.62 0.65
EV/Sales 15.90 6.45 8.98
Earnings yield (4.07%) 5.03% (34.89%)
Free cash flow yield (2.58%) 6.74% (24.52%)

Profitability

Metric BBIO EXEL Biotechnology median
Gross margin 94.34% 96.26% 65.16%
Operating margin (38.52%) 40.19% 0.00%
Net margin (62.62%) 35.45% 0.00%
Free cash flow margin (39.11%) 45.84% 0.00%
Return on equity 26.22% 44.32% (50.12%)
Return on assets (37.48%) 33.17% (45.60%)
Return on invested capital 0.00% 66.59% 0.00%

Growth

Metric BBIO EXEL Biotechnology median
Revenue growth (TTM) 167.27% 9.12% 6.26%
EPS growth (last fiscal year) (31.25%) 57.95% 29.88%
Revenue growth, 5-year CAGR 127.44% 18.63% 9.75%
Net income growth, 5-year CAGR 0.00% 47.58% 0.00%

Health

Metric BBIO EXEL Biotechnology median
Debt to equity (1.17) 0.00 0.00
Current ratio 2.09 3.21 4.89
Net debt to EBITDA (2.47) (1.18) 1.01

Dividend

Metric BBIO EXEL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BBIO EXEL Biotechnology median
Market cap 14.47b 16.77b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack